Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Allergy Clin Immunol. 2020 Apr 25;146(3):571–582.e3. doi: 10.1016/j.jaci.2020.03.039

Figure 6. Rorafl/flIl7rcre ILC2-deficient mice are protected from heterologous infection induced exaggerated type 2 inflammation and mucous metaplasia.

Figure 6.

A) Flow cytometry analysis of lineage-, CD25+, CD127+ ILC2s. N=2-4 per group B) BAL inflammatory cell counts and C) mRNA expression in sham + sham, RV-A1B + sham, sham + RV-A2 and RV-A1B + RV-A2-infected Rorafl/fl and Rorafl/flIl7rcre ILC2-deficient mice. For panels B and C, N=3-6 per group. For panels A-C, data are mean ± SEM; *different from sham + sham group of like mouse strain, †different from RV-A1B + sham of like mouse strain, ‡different from corresponding group in Rorafl/fl mouse strain, P < 0.05 by one-way ANOVA and Tukey multiple comparison test. D). Viral copy number in RV-A1B + RV-A2-infected Rorafl/fl and Rorafl/flIl7rcre ILC2-deficient mice. E. PAS-stained representative airways from RV-A1B + RV-A2-infected Rorafl/fl mice (left) and Rorafl/flIl7rcre ILC2-deficient mice (right). The black bar is 50 μ. F) Changes in total respiratory system resistance in response to inhaled methacholine in anesthetized, tracheotomized Rorafl/fl and Rorafl/flIl7rcre mice. Resistance data were normalized to baseline airways resistance. Data are mean ± SEM for 3-10 per group measured in 3 different experiments, *different from Rorafl/fl mice, P < 0.05 by two-way ANOVA and Tukey multiple comparison test.